HeartSciences (HSCS) Stock News, Mar-Aug 2025

HeartSciences (NASDAQ: HSCS) reported its fiscal 2025 results and business updates, highlighting significant progress in AI-powered ECG technology. The company's flagship MyoVista Insights™ cloud-native software platform launched in May 2025, designed to modernize ECG management systems and serve as a marketplace for AI-ECG algorithms.

Key developments include: CMS approval for AI-ECG algorithm reimbursement at $128 per test, FDA Breakthrough Device designation for their aortic stenosis algorithm, and expansion to 44 granted patents worldwide. The company is preparing for FDA 510(k) submission of its MyoVista wavECG™ device and targets FDA submission of its first cloud-based algorithm for detecting reduced ejection fraction in early 2026.

Financially, HeartSciences reported $1.1 million in cash as of April 30, 2025, and subsequently raised $3.1 million through a Reg A+ offering and converted $0.9 million of debt to equity.

HeartSciences (HSCS) has received FDA Breakthrough Device designation for its AI-powered ECG algorithm designed to detect aortic stenosis. The algorithm, accessible through MyoVista Insights cloud platform, can identify moderate-to-severe aortic stenosis up to 24 months before confirmatory echocardiography. Developed using convolutional neural network deep learning and trained on 120,000+ ECG records, the technology integrates directly with hospital EHR systems without requiring additional hardware. The solution aims to address the critical need for early detection of aortic stenosis, a serious heart valve disease that often progresses silently and can lead to life-threatening outcomes if left untreated. The algorithm offers real-time and retrospective analysis capabilities using existing ECG data and promises expanded access to early diagnosis, particularly in underserved areas.

HeartSciences (NASDAQ: HSCS) has been granted a significant US patent for ECG-based heart function assessment technology. The patent specifically covers the estimation of echocardiography parameters using ECG data, crucial for early heart disease detection. This addition strengthens HeartSciences' intellectual property portfolio, which now comprises 44 total patents - 10 US patents and 34 international patents across major markets including China, Brazil, Canada, India, South Korea, Mexico, and European countries. The company's AI-powered technology aims to transform traditional ECG/EKG capabilities for improved heart disease detection. CEO Andrew Simpson emphasized this patent's importance in establishing HeartSciences as a key player in the AI-ECG field and highlighted its contribution to the company's IP value.

HeartSciences (NASDAQ: HSCS) has secured its first commercial customer, Westcliffe Health Innovations in the UK, for its MyoVista Insights™ platform. This cloud-native ECG management system is designed to be the first vendor- and device-agnostic platform capable of running AI-ECG algorithm models from multiple partners. The implementation will serve as a key reference site within the UK market, particularly for the National Health Service (NHS).

Westcliffe Health Innovations, led by Dr. Matthew Fay, provides cardiology services to the NHS in the Bradford and Leeds region. The partnership aims to enhance clinical decision-making and improve healthcare IT efficiency by streamlining ECG workflows and reducing operational costs. This milestone follows the recent launch of MyoVista Insights and its early adopter program earlier this month.

HeartSciences (Nasdaq: HSCS) announced that CEO Andrew Simpson will present at the Emerging Growth Conference 82 on Wednesday, May 21, 2025 at 10:15 AM EDT. The virtual presentation will include a live Q&A session, providing investors insight into the company's AI-ECG platform and mission.

HeartSciences specializes in AI-powered medical technology focused on transforming ECGs/EKGs for earlier heart disease detection. The presentation will highlight their AI-ECG platform, designed to enhance standard ECG diagnostic capabilities at the point of care. Simpson will also discuss a current Regulation A investment opportunity available to qualified investors.

HeartSciences (Nasdaq: HSCS) has announced an upcoming investor webinar scheduled for Wednesday, May 14, 2025, at 2:00 p.m. EDT. The event will feature CEO Andrew Simpson who will present and conduct a Q&A session focusing on the company's AI-powered ECG/EKG technology platform. The webinar will provide insights into HeartSciences' mission to transform early heart disease detection and its market opportunities. Simpson will also discuss a Regulation A investment opportunity available to qualified investors.

HeartSciences (Nasdaq: HSCS) has strengthened its Scientific Advisory Board with the addition of three distinguished experts in cardiology and AI: Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid. Dr. Nadkarni, currently serving as Fishberg Professor of Medicine and Director at Mount Sinai, brings extensive expertise with over 375 peer-reviewed publications and 40,000 citations. Dr. Lampert, a cardiac electrophysiologist and Medical Director of Machine Learning at Mount Sinai Fuster Heart Hospital, specializes in heart rhythm disorders and AI applications. Dr. Vaid, an Assistant Professor focusing on AI in healthcare, contributes significant experience in developing AI models for cardiac analysis. These appointments align with HeartSciences' mission to transform ECG technology through AI for earlier heart disease detection.

HeartSciences (NASDAQ: HSCS) has launched its MyoVista Insights™ platform, a cloud-native ECG Management System designed to enhance clinical decision-making and healthcare IT efficiency. The platform features vendor-agnostic integration capabilities for AI-ECG algorithms, a unique prioritization system, and standardized ECG reporting protocols.

Key features include patient-centric longitudinal comparisons, disease progression tracking, and enhanced workflow efficiency. Built on AWS technology stack, MyoVista Insights offers a pay-as-you-go model, reducing implementation and storage costs compared to legacy systems. The platform will integrate both company-developed and third-party AI-ECG algorithms in future releases to help identify patients requiring further cardiac testing earlier.

HeartSciences (HSCS) reported Q3 FY2025 financial results and business updates, highlighting significant progress in AI-powered ECG technology. The company reported no revenues for Q3 FY2025, with cash and cash equivalents of $2.6 million and shareholders' equity of $1.8 million as of January 31, 2025.

Key developments include:

• Final pre-submission meeting with FDA for MyoVista wavECG device in February 2025, with expected FDA clearance submission in H1 2025
• Successful completion of Phase 1 MyoVista Insights cloud-native platform in December 2024
• Pre-validation work completed with Rutgers for low ejection fraction algorithm
• CMS 2025 OPPS final rule inclusion enabling reimbursement upon commercial launch

The company's strategy focuses on modernizing ECG technology through AI-enhanced hardware and software solutions, positioning itself as the only company building next-gen ECG device hardware, device-agnostic cloud-native software, and AI-ECG algorithms.